Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Cardiol Therapeutics Inc. files with the SEC in its annual reports.
In CAD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.08
Research and development
10.6
10.9
19
14.2
14
14
Operating income
-20.7
-38.7
-41.3
-29.8
-40.3
-34.3
Income tax
0
0
0
Net income
-20.6
-31.6
-30.9
-28.1
-36.7
-33.8
EPS, basic
-0.69
-0.73
-0.49
-0.44
-0.51
-0.39
EPS, diluted
-0.69
-0.73
-0.49
-0.44
-0.51
-0.39
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
14
83.9
59.5
34.9
30.6
21.4
Inventory
0.02
Total current assets
14.9
87.1
61.4
36.2
31.7
23.5
Property, plant and equipment
0.48
0.36
0.3
0.34
0.2
0.12
Lease right-of-use assets
0.14
0.1
Intangible assets
0.77
0.38
0.29
0.21
Total assets
15.9
87.9
62
36.7
31.9
23.6
Accounts payable
2.47
4.86
9.33
8.04
6.98
3.48
Total current liabilities
2.52
11.6
9.8
8.3
7.01
5.66
Lease liabilities
0.1
0.07
0.02
0.16
0.13
0.09
Total liabilities
2.62
11.6
9.83
8.45
7.14
5.74
Paid-in capital
8.77
12.7
15.6
18.8
24.6
29.1
Retained earnings
-51.9
-83.5
-114
-143
-179
-213
Total equity
13.3
76.2
52.2
28.2
24.7
17.9
Total liabilities and equity
15.9
87.9
62
36.7
31.9
23.6
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-20.6
-31.6
-30.9
-28.1
-36.7
-33.8
Cash from operations
-9.13
-23.5
-27.2
-25.2
-25.1
-23.9
Capital expenditures
-0.04
-0.01
-0.07
-0.06
-0.02
-0.02
Cash from investing
-0.04
-0.01
-0.07
-0.06
-0.02
-0.02
Stock issued
17.3
84.1
21.4
16
Cash from financing
16.3
93.4
-0.05
-0.06
18.8
15.5
Net change in cash
7.13
69.9
-27.3
-25.3
-6.24
-8.34
Free cash flow
-9.17
-23.6
-27.3
-25.2
-25.1
-23.9
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-121.9%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
-25.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-27.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
8.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.16x
Current assets / current liabilities.
Quick ratio
3.79x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.79x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
24.3%
Total liabilities / total assets.
Working capital
CA$17.8M
Current assets - current liabilities.
Per share
Metric
Value
How it is calculated
EPS, diluted
-CA$0.39
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-CA$0.39
Net income per basic share, as reported (split-adjusted).
Was Cardiol Therapeutics Inc. profitable in fiscal 2025?
No. It reported a net loss of CA$33.8M.
How much free cash flow did Cardiol Therapeutics Inc. generate in fiscal 2025?
Cash from operations of CA$23.9M minus capital expenditures of CA$24.5K left free cash flow of -CA$23.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.